PCI Biotech to present at BioTrinity 2014

Oslo, May 12 2014 - PCI Biotech will be presenting at BioTrinity 2014.About BioTrinity 2014 (12-14 May 2014, Novotel London West, UK):

BioTrinity 2014 builds on its established reputation as the largest UK-focused biopartnering and investment conference, the powerhouse of partnering which brings together a critical mass of active investors, global pharma and innovative biotech and medtech companies. The full two-day conference program features a showcase of the best emerging and clinical stage companies from across Europe.The presentation will be held 13 May local time 14:30 and the company will be represented by Mr. Gaël L'Hévéder, CBDO.

About PCI Biotech

PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed treatment system based on its patented photochemical internalisation (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting the photosensitiser Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When the diseased cells are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.

PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules, drugs carried by antibodies or nanoparticles, as well as some small molecule drugs.The PCI technology is also a versatile and innovative vaccination platform, which may specifically increase the cytotoxic T-cell response of vaccines. This is particularly important in therapeutic vaccination, when the immune system needs to recognise and destroy diseased cells (e.g. virus infected cells and cancer).

PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.

For more information visit: www.pcibiotech.com

For further information, please contact
Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.